SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venmax Drugs & Pharmaceuticals submits unaudited standalone financial results

23 Jul 2025 Evaluate

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Venmax Drugs & Pharmaceuticals has informed that it enclosed the Un-audited Standalone Financial Results along with Limited Review Report of the Statutory Auditors of the company, PPKG & Co Chartered Accountants for the quarter ended 30th June, 2025. The Financial Results are also available on the website of the Company at www.venmaxdrugs.com and on the website of BSE www.bseindia.com. The Board Meeting commenced at 02:00 pm and concluded at 03:20 pm.

The above information is a part of company’s filings submitted to BSE. 


Venmax Drugs&Pharma Share Price

24.00 -0.06 (-0.25%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×